Methylation level of Rap1GAP and the clinical significance in MDS

被引:8
作者
Ding, Wen-Jing [1 ]
Yang, Yi [1 ]
Chen, Zi-Xing [1 ]
Wang, Yuan-Yuan [1 ]
Dong, Wan-Li [1 ]
Cen, Jian-Nong [1 ]
Qi, Xiao-Fei [1 ]
Jiang, Feng [1 ]
Chen, Su-Ning [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostasis,Minist Hlth, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China
关键词
myelodysplastic syndrome; RAP1GTPase activating protein 1 methylation level; MYELODYSPLASTIC SYNDROME MDS; DNA METHYLATION; DOWN-REGULATION; SCORING SYSTEM; INVASION; PROGRESSION; EXPRESSION; CELLS;
D O I
10.3892/ol.2018.9503
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies on the pathogenesis of myelodysplastic syndrome (MDS) have identified multiple associated gene mutations, including mutations of tetmethylcytosinedioxygenase 2, isocitrate dehydrogenase [NADP(+)] 1 cytosolic, isocitrate dehydrogenase [NADP(+)] 2 mitochondrial and additional sex combs like 1 transcriptional regulator, all of which may be considered epigenetic regulators. Furthermore, mutations of RAS type GTPase family genes have been identified in 10-15% patients with MDS. The authors' previous study on the gene expression profile of cluster of differentiation 34(+) cells using microarray analysis identified elevated expression of RAP1GTPase activating protein 1 (Rap1GAP) in patients with MDS compared with that in non-malignant blood diseases (NM) control group. To further investigate the mechanism of increased Rap1GAP expression, the methylation pattern of the promoter of this gene was determined in 86 patients with MDS (n=29), acute myeloid leukemia (AML) (n=31) or NM (n=26) using bisulfite-specific polymerase chain reaction and DNA sequencing. The results demonstrated that the methylation of Rap1GAP occurred in all 29 patients with MDS at multiple CpG sites. The methylation level of Rap1GAP in patients with MDS was decreased compared with that in patients with NM. Significant differences at 4CpG sites (5,7,8 and 12) of Rap1GAP promoter were identified between MDS and NM. Furthermore, based on the present clinical records of the patient cohort, the methylation status of Rap1GAP promoter did not appear to be associated with the clinicopathological characteristics of patients with MDS, including age, gender and International Prognosis Score System. The difference in methylation level at CpG site 8 of Rap1GAP promoter was identified to be significantly increased in patients with MDS-refractory anemia with ring sideroblasts compared with that in the MDS-refractory cytopenia with multilineage dysplasia or MDS-unclassified groups. The results of the present study suggest that patients with MDS exhibit a lower overall methylation level within Rap1GAP promoter compared with patients with NM or AML. In addition, the methylation level at the four identified CpG sites can distinguish between MDS and NM.
引用
收藏
页码:7287 / 7294
页数:8
相关论文
共 23 条
  • [1] From FAB to 2008 WHO classification: The wide heterogeneity of refractory anemia subtype among different countries
    Breccia, Massimo
    [J]. LEUKEMIA RESEARCH, 2010, 34 (08) : 967 - 968
  • [2] Deschler B, 2006, HAEMATOLOGICA, V91, P1513
  • [3] International scoring system for evaluating prognosis in myelodysplastic syndromes
    Greenberg, P
    Cox, C
    LeBeau, MM
    Fenaux, P
    Morel, P
    Sanz, G
    Sanz, M
    Vallespi, T
    Hamblin, T
    Oscier, D
    Ohyashiki, K
    Toyama, K
    Aul, C
    Mufti, G
    Bennett, J
    [J]. BLOOD, 1997, 89 (06) : 2079 - 2088
  • [4] The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)
    Hasle, H
    Baumann, I
    Bergsträsser, E
    Fenu, S
    Fischer, A
    Kardos, G
    Kerndrup, G
    Locatelli, F
    Rogge, T
    Schultz, KR
    Stary, J
    Trebo, M
    van den Heuvel-Eibrink, MM
    Harbott, J
    Nöllke, P
    Niemeyer, CM
    [J]. LEUKEMIA, 2004, 18 (12) : 2008 - 2014
  • [5] Ika Stella Aprilia, 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V17, P612
  • [6] The myelodysplastic syndrome as a prototypical epigenetic disease
    Issa, Jean-Pierre J.
    [J]. BLOOD, 2013, 121 (19) : 3811 - 3817
  • [7] Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    Jiang, Ying
    Dunbar, Andrew
    Gondek, Lukasz P.
    Mohan, Sanjay
    Rataul, Manjot
    O'Keefe, Christine
    Sekeres, Mikkael
    Saunthararajah, Yogen
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2009, 113 (06) : 1315 - 1325
  • [8] DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy
    Keller, Simona
    Angrisano, Tiziana
    Florio, Ermanno
    Pero, Raffaela
    Decaussin-Petrucci, Miriam
    Troncone, Giancarlo
    Capasso, Mario
    Lembo, Francesca
    Fusco, Alfredo
    Chiariotti, Lorenzo
    [J]. ONCOLOGY LETTERS, 2013, 6 (01) : 86 - 90
  • [9] Rap1GAP regulates renal cell carcinoma invasion
    Kim, Wan-Ju
    Gersey, Zachary
    Daaka, Yehia
    [J]. CANCER LETTERS, 2012, 320 (01) : 65 - 71
  • [10] The biology and clinical impact of genetic lesions in myeloid malignancies
    Lindsley, R. Coleman
    Ebert, Benjamin L.
    [J]. BLOOD, 2013, 122 (23) : 3741 - 3748